Skip to main content

Table 2 Clinical management and outcome

From: Clinical characteristics and risk factors of patients with severe COVID-19 in Jiangsu province, China: a retrospective multicentre cohort study

 

n (%) or median (IQR)

P-value

Severe/Critically ill

 

Category

Clinical management and outcome

Yes (N = 64)

No (N = 561)

All (N = 625)

Supportive treatments

Inotropic and vasoconstrictive agents

5(7.8%)

0(0.0%)

5(0.8%)

<.0001

Nasal cannula

53(82.8%)

168(29.9%)

221(35.4%)

<.0001

Mask

12(18.8%)

2(0.4%)

14(2.2%)

<.0001

High-flow nasal cannula oxygen therapy

24(37.5%)

1(0.2%)

25(4.0%)

<.0001

Non-invasive ventilation

34(53.1%)

0(0.0%)

34(5.4%)

<.0001

Intermittent mandatory ventilation

5(7.8%)

0(0.0%)

5(0.8%)

<.0001

Prone position

17(26.6%)

1(0.2%)

18(2.9%)

<.0001

Continuous renal replacement therapy

1(1.6%)

0(0.0%)

1(0.2%)

0.1024

Extracorporeal membrane oxygenation

2(3.1%)

0(0.0%)

2(0.3%)

0.0103

Lung transplantation

2(3.1%)

0(0.0%)

2(0.3%)

0.0103

Medical drugs

Traditional Chinese medicine

29(45.3%)

69(12.3%)

98(15.7%)

<.0001

Immunoglobulin

50(78.1%)

106(18.9%)

156(25.0%)

<.0001

Interferon

47(73.4%)

456(81.3%)

503(80.5%)

0.1363

Antioxidants

35(54.7%)

117(20.9%)

152(24.3%)

<.0001

Glucocorticoid

52(81.3%)

90(16.0%)

142(22.7%)

<.0001

Thymosin

43(67.2%)

101(18.0%)

144(23.0%)

<.0001

Neurotrophic drugs

21(32.8%)

81(14.4%)

102(16.3%)

0.0005

Any antibiotics

59(92.2%)

277(49.4%)

336(53.8%)

<.0001

Any antivirals

64(100%)

516(92.0%)

580(92.8%)

0.0098

Clinical outcome

Death

0(0.0%)

0(0.0%)

0(0.0%)

NC

Hospital stay

21.5(15.0–29.0)

15.0(12.0–21.0)

16.0(12.0–22.0)

<.0001